Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24133492 | 0.82 | SLC6A4 (0.38) | EGFRSLC6A4AAK1 | |
| SCHEMBL30408614 | 0.82 | SLC6A4 (0.38) | EGFRSLC6A4AAK1 | |
| SCHEMBL24133487 | 0.82 | SLC6A4 (0.38) | EGFRSLC6A4AAK1 | |
| SCHEMBL24133484 | 0.75 | SLC6A4 (0.43) | HTR2CSLC6A4HTR2BHTR6 | |
| SCHEMBL31402228 | 0.75 | SLC6A4 (0.43) | HTR2CSLC6A4HTR2BHTR6 | |
| SCHEMBL29024307 | 0.75 | SLC6A4 (0.43) | HTR2CSLC6A4HTR2BHTR6 | |
| SCHEMBL24133606 | 0.72 | LPL (0.48) | SLC6A4AAK1 | |
| SCHEMBL25891327 | 0.72 | LPL (0.48) | SLC6A4AAK1 | |
| SCHEMBL31319099 | 0.71 | CA1 (0.35) | EGFRSLC6A4AAK1 | |
| SCHEMBL25706906 | 0.71 | CA1 (0.35) | EGFRSLC6A4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | EGFR 2690/4885HTR2C 4257/4885SLC6A4 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.